-+ 0.00%
-+ 0.00%
-+ 0.00%

How Investors Are Reacting To Nektar Therapeutics (NKTR) Phase 3 Trial Starts

Simply Wall St·11/15/2026 10:32:20
Listen to the news
  • Nektar Therapeutics recently reported Q3 2026 results showing revenue of US$9.39 million and a net loss of US$55.65 million, while also advancing rezpegaldesleukin into multiple Phase 3 programs in atopic dermatitis and alopecia areata, with a long cash runway and no debt.
  • The combination of a Treg-focused REZPEG platform in large underpenetrated immunology indications and a sizable cash position gives Nektar Therapeutics room to keep funding late stage trials, despite limited current revenue and continued losses.
  • We will now look at how Nektar Therapeutics’ Phase 3 REZPEG program could reshape the existing investment narrative around its losses.

Scan beyond Nektar Therapeutics and see how other cash rich, late stage developers stack up using our hand picked 19 high quality undiscovered gems in the same high risk, high upside bracket.

Nektar Therapeutics Investment Narrative Recap

To own Nektar Therapeutics you need to believe that rezpegaldesleukin can move from late stage development to a commercial product across atopic dermatitis, alopecia areata and potentially other immune conditions. The recent Q3 report reinforced the current reality: modest revenue, a sizeable net loss and a large cash balance are funding a long, research heavy phase.

The short term story still hinges on execution of the Phase 3 ZENITH program and keeping the balance sheet strong enough to avoid untimely capital raises. The widening quarterly and year to date losses highlight the key risk. If timelines slip or trial costs rise, dilution risk and pressure on future economics increase.

The most relevant recent update is the formal launch of the global Phase 3 ZENITH program for REZPEG in atopic dermatitis and alopecia areata. Management also raised its year end cash forecast, ending Q3 with about US$953 million in cash and no debt, which matters for funding these long duration trials.

For catalysts, that ZENITH program, including top line ZENITH AD data targeted for summer 2028 and a planned BLA filing by late 2029, is the focal point in the analyst consensus Narrative on Simply Wall St. Between now and then, investors are mainly watching operational markers. Enrollment pace, safety updates and cash burn will shape how much financing risk sits between today and those readouts.

Nektar Therapeutics' current analyst narrative points to forecast revenue of US$38.8 million and projected earnings of US$7.1 million by 2029, based on an assumed 10.7% yearly decline in revenue and an earnings swing of about US$164.2 million from a loss of US$157.1 million today.

Uncover why Nektar Therapeutics' fair value indicates a 257% potential upside to its current price, which could narrow quickly.

NasdaqCM:NKTR 1-Year Stock Price Chart
NasdaqCM:NKTR 1-Year Stock Price Chart

Exploring Other Perspectives

One bullish twist in the alternate Nektar Therapeutics story is the focus on revenue expansion. The most optimistic analysts were pencilling in revenue of about US$95.2 million and earnings of roughly US$16.4 million by 2029, compared with the more cautious consensus near US$38.8 million. These views were all formed before this Q3 update, so treat them as starting points that may shift, and use them to test your own expectations across a wide range of possible outcomes.

Explore 2 other Nektar Therapeutics fair value estimates, including one that suggests potential upside of as much as 415% from the current price.

Reach Your Own Conclusion

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking For More Investment Ideas Beyond Nektar Therapeutics?

If the Nektar Therapeutics story has sharpened your thinking around risk, balance sheets and late stage pipelines, it can help to widen the lens and compare it with other opportunities using the Simply Wall St Screener.

  • For investors who care most about financial resilience, start with companies that pair strong balance sheets with solid fundamentals by reviewing our list of solid balance sheet and fundamentals (24 results).
  • If steadier return potential and income matter more to you, focus on businesses with robust payouts through the 6 dividend fortresses that filters for higher yielding dividend payers.
  • For those hunting for mispriced opportunities with room for a re rating, scan through our 34 high quality undervalued stocks to see which stocks currently screen as both high quality and out of favour.